Peptide Profile

Ipamorelin

Growth Hormone-Releasing Peptide (GHRP)

Research Only10 sourcesShop Ipamorelin

Overview

Composition

Synthetic pentapeptide growth hormone secretagogue (GHS) that selectively binds to ghrelin/growth hormone secretagogue receptor (GHS-R1a)

Mechanism of Action

Stimulates pulsatile growth hormone (GH) release from the anterior pituitary without significantly elevating cortisol, prolactin, or ACTH—mimicking natural GH secretion patterns

Primary Effects

Studied for selective GH release and downstream body-composition, recovery, sleep, and bone-density endpoints, with human outcome evidence much thinner than animal and mechanistic evidence

Discovery & Background

Developed in the late 1990s as part of research to create highly selective GH secretagogues with improved safety profiles compared to earlier GHRPs

Research expanded through the 2000s with focus on selectivity for GH release. By the 2010s, commercial wellness use had outpaced the depth of controlled human evidence.

Not FDA-approved for therapeutic use; remains investigational/research compound, commonly used off-label in compounded form

Research Overview

Preclinical and clinical studies demonstrate ipamorelin's selective GH-releasing effects with minimal impact on other hormones

01
Selective GH release without significant cortisol or prolactin elevation
02
Increases lean body mass and reduces body fat in animal models
03
Bone-density and collagen-synthesis claims are mostly mechanistic or preclinical
04
Sleep-quality and recovery-marker claims remain less directly supported in controlled human studies
05
Human evidence remains much thinner than animal and mechanistic evidence
06
Well-tolerated with mild side effects in short-term studies
07
Combination claims with CJC-1295 are largely mechanistic and not supported by large standardized trials

No FDA approval; lacks large-scale human RCTs for therapeutic claims. Used extensively in research, wellness, and compounded applications

Safety Considerations

Monitoring

IGF-1 levels
Body composition changes
Sleep quality
Recovery markers
Fasting glucose and insulin sensitivity

Side Effects

Common (Mild)

Headache or flushing has been reported
Transient tiredness or lightheadedness may occur
Increased hunger (ghrelin mimetic effect)
Water retention (mild)
Tingling or numbness in extremities

Rare

Hypoglycemia (low blood sugar)
Changes in insulin sensitivity with prolonged use

Contraindications

Active cancer or tumor history (GH can promote cell proliferation)
Diabetic retinopathy or proliferative conditions
Hypersensitivity to ipamorelin or components
Caution in diabetes or metabolic disorders (monitor glucose)

Educational Notice

Ipamorelin is a selective growth hormone secretagogue, but it is not FDA-approved for therapeutic use and remains investigational. Evidence for body composition, recovery, sleep, and aging-related claims is primarily mechanistic, animal-based, small-study, or uncontrolled. Long-term human safety data are limited, compounded quality varies, and clinical decisions require qualified medical oversight.

References